@article{44c48db8644546ceae2cfc49479f7ee7,
title = "Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year",
abstract = "In 2021 the BMT CTN held the 4th State of the Science Symposium where the deliberations of 11 committees concerning major topics pertinent to a particular disease, modality, or complication of transplant, as well as two committees to consider clinical trial design and inclusion, diversity, and access as cross-cutting themes were reviewed. This article summarizes the individual committee reports and their recommendations on the highest priority questions in hematopoietic stem cell transplant and cell therapy to address in multicenter trials.",
keywords = "BMT, Cell Therapy, Clinical Trial",
author = "Heslop, {Helen E.} and Stadtmauer, {Edward A.} and Levine, {John E.} and Ballen, {Karen K.} and Chen, {Yi Bin} and DeZern, {Amy E.} and Mary Eapen and Mehdi Hamadani and Hamilton, {Betty K.} and Parameswaran Hari and Jones, {Richard J.} and Logan, {Brent R.} and Kean, {Leslie S.} and Leifer, {Eric S.} and Locke, {Frederick L.} and Maziarz, {Richard T.} and Nemecek, {Eneida R.} and Marcelo Pasquini and Rachel Phelan and Riches, {Marcie L.} and Shaw, {Bronwen E.} and Walters, {Mark C.} and Amy Foley and Devine, {Steven M.} and Horowitz, {Mary M.}",
note = "Funding Information: Financial disclosure: Support for this study was provided by Grants U10HL069294 and U24HL138660 to the BMT CTN from the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and UG1 awards to the core centers. The CIBMTR registry is supported primarily by Grant U24CA76518 from the NCI, the NHLBI, and the National Institute of Allergy and Infectious Diseases and by Contract HHSH234200637015C to the CIBMTR from the Health Resources and Services Administration/Department of Health and Human Services. Conflict of interest statement: H.E.H. has equity in Allovir and Marker Therapeutics; has served on advisory boards for Gilead Sciences, Kiadis Pharma, Novartis, GSK, and Tessa Therapeutics; and has received research support from Tessa Therapeutics and Kuur Therapeutics. J.E.L. is a co-inventor of a GVHD biomarkers patent and receives royalties from Viracor, consulting fees and research support from Incyte, and research support from Kamada and Biogen. R.P. reports research support from Amgen. R.T.M. serves as a consultant for AlloVir, Artiva, CRISPR Therapeutics, Incyte, and Novartis; has received honoraria from Bristol-Myers Squibb, Incyte, Intellia, Gilead, Omeros, Orca BioSystems, and PACT Pharma; has received research support from Bristol-Myers Squibb and Novartis; has served on Data and Safety Monitoring Boards for Athersys, Novartis and Vor Pharmaceutials; and holds a patent with Athersys. Financial disclosure: See Acknowledgments on page 905. Funding Information: By the end of the 20th century, significant advancements in allogeneic hematopoietic cell transplantation (alloHCT) techniques had resulted in marked improvements in overall survival (OS) compared with its earliest days. Yet many in the field believed progress could be accelerated if there was a collaborative, adequately funded, and effective infrastructure for clinical trials that could definitively test potential breakthrough therapies. In 2000, the National Institutes of Health (NIH) recognized there were gaps in translating scientific discoveries, funded predominantly through independent investigator R01 awards, into novel therapies that could change HCT practice. To address this deficiency, in 2001 the NIH issued a request for applications (RFA HL-01-004) to establish the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The Network is jointly funded by the National Heart, Lung, and Blood Institute (lead institution) and the National Cancer Institute (NCI). Funding Information: Financial disclosure: Support for this study was provided by Grants U10HL069294 and U24HL138660 to the BMT CTN from the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and UG1 awards to the core centers. The CIBMTR registry is supported primarily by Grant U24CA76518 from the NCI, the NHLBI, and the National Institute of Allergy and Infectious Diseases and by Contract HHSH234200637015C to the CIBMTR from the Health Resources and Services Administration/Department of Health and Human Services. Publisher Copyright: {\textcopyright} 2021 The American Society for Transplantation and Cellular Therapy",
year = "2021",
month = nov,
doi = "10.1016/j.jtct.2021.08.016",
language = "English",
volume = "27",
pages = "885--907",
journal = "Transplantation and Cellular Therapy",
issn = "2666-6375",
publisher = "Elsevier BV",
number = "11",
}